61. Autoimmune hemolytic anemia Clinical trials / Disease details


Clinical trials : 137 Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2031210392
07/12/202127/10/2021Sutimlimab (BIVV009) for the adult participants with cold agglutinin disease (CAD) who have completed Phase 3 studies (CARDINAL or CADENZA) in JapanAn open-label study for sutimlimab in participants with cold agglutinin disease (CAD) who have completed the CARDINAL study (BIVV009-03/EFC16215, Part B) or CADENZA study (BIVV009-04/EFC16216, Part B) in Japan Cold Agglutinin DiseaseDrug: sutimlimab (BIVV009)
Pharmaceutical Form: solution for injection, Route of Administration: intravenous(iv)
Tanaka TomoyukiNULLNot Recruiting>= 20age oldNot applicableBoth7Phase 3Japan
2NCT05132127
(ClinicalTrials.gov)
November 11, 202111/11/2021Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in JapanAn Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in JapanCold Agglutinin DiseaseDrug: sutimlimabSanofiNULLActive, not recruiting20 YearsN/AAll7Phase 3Japan
3NCT03347422
(ClinicalTrials.gov)
March 17, 201816/11/2017A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood TransfusionA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood TransfusionCold Agglutinin DiseaseDrug: sutimlimab (BIVV009);Drug: placeboBioverativ, a Sanofi companyNULLCompleted18 YearsN/AAll42Phase 3United States;Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom